Author’s response to reviews

Title: The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

Authors:

Manabu Kakizoe (makakizoe@yahoo.co.jp)
Masahiro Yao (masayao@med.yokohama-cu.ac.jp)
Ukihide Tateishi (utateish@yokohama-cu.ac.jp)
Ryogo Minamimoto (ryogominamimoto@yahoo.co.jp)
Kazuhide Makiyama (makiya@yokohama-cu.ac.jp)
Narihiko Hayashi (twnary@yahoo.co.jp)
Futoshi Sano (fsano@yokohama-cu.ac.jp)
Takeshi Kishida (kishidat@kcch.jp)
Kazuki Kobayashi (kazuki1010@ybb.ne.jp)
Sumio Noguchi (sn0818@kfu6.so-net.ne.jp)
Ichiro Ikeda (iichiban@yahoo.co.jp)
Yoshiharu Ohgo (y-oogo@yokohamasakae.jp)
Masaharu Taguri (taguri@yokohama-cu.ac.jp)
Satoshi Morita (smorita@kuhp.kyoto-u.ac.jp)
Tomio Inoue (tomioi@yokohama-cu.ac.jp)
Yoshinobu Kubota (kubotayo@med.yokohama-cu.ac.jp)
Noboru Nakaigawa (nakaigan@med.yokohama-cu.ac.jp)

Version: 2
Date: 22 December 2013

Author’s response to reviews:

Dear Editor

I am glad to send you our research article titled “The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ”.

Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that FDG PET/CT as a useful tool to evaluate the biological response to tyrosine kinase inhibitor (TKI) in advanced renal cell carcinoma (RCC) (BMC Cancer 2012, 12: 162). So, in this paper, we focused on the difference in the FDG accumulation among various organs where the RCC metastasis was located and demonstrated that the decrease ratio of FDG accumulation of RCC lesions evaluated by FDG PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. Our result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site. We hope that our information will support many urologists to decide the optimal management for individual
patients with advanced RCC and provide clinical benefit for many patients suffering RCC.

Noboru Nakaigawa MD & PhD
Associate Professor
Department of Urology Yokohama City University School of Medicine
3-9, Fukuura, Kanazawa-ku Yokohama 236-0004 Japan
Tel: 81-45-787-2679
Fax: 81-45-786-5531
E-mail: nakaigan@med.yokohama-cu.ac.jp